Search This Blog

Monday, 22 February 2021

Obesity. A new breakthrough treatment? Or the promotion of another failed and unsafe drug with serious known side effects?

Earlier this month another new 'wonder drug' was announced in the mainstream media (MSM), who provide advertising for the pharmaceutical industry, free of charge. BBC News set the general tone with its headline.cons

"Obesity: Appetite drug could mark 'new era' in tackling condition"

The problem with these pharmaceutical news releases, dutifully repeated by the MSM, is that they invariably come to nothing. The 'new era' does not happen.

Nor are the known adverse drug reactions. Perhaps there is a mention of some minor side effects later in the article. The drug referred to here is semaglutide. It's not a new drug. It has a long list of serious side effects but these are glossed over. On this link there is a clear warning at the top of the page, there are side effects that you need to 'check with your doctor', and a very long list of known adverse reactions that go far beyond the nausea, diarrhoea, vomiting and constipation the BBC article chooses to mention.

But no matter, The intended message is that conventional medicine has discovered yet another new treatment for a very serious problem. We are reminded not only of this, but the fact that obesity can lead to much more serious outcomes, including heart disease, diabetes and severe Covid-19. So provide warnings of the consequences of the condition, whilst emphasising the 'game changing' effects of the drug. It is an advertising strategy designed to produce queues at the doctors surgery.

When this drug strategy works, when or if the obesity epidemic is reduced by semaglutide, I will return to this subject. I will also return to it when (or if) the drug is withdrawn or banned - because it has caused more serious patient harm than even the drug companies are able to justify.